^
Association details:
| Biomarker: | EGFR H773_V774insH |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | ORIC-114 (HER2 exon 20 mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ORIC-114, an orally bioavailable, irreversible kinase inhibitor,?has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models
Published date:
03/09/2022
Excerpt:
Consistent with in vitro potency and selectivity, once daily oral administration of 3 mg/kg ORIC-114 induced robust tumor regressions with greater than 100% tumor growth inhibition in the absence of significant body weight loss in an EGFR exon 20 insertion H773_V774insNPH NSCLC PDX model.
